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A crucial step in the isolation of antibiotic substances is establishing whether or not the 
isolated material represents a new chemical entity. Because of the importance of molecular 
weight to this process-known as dereplication-mass spectrometry has traditionally played 
an active role. In this communication a strategy for utilizing liquid chromatography-mass 
spectrometry (LC/MS) for novelty assessment is described. Crude extracts (20-50 pg) are 
chromatographed by conventional bore high-performance liquid chromatography (1 mL/min) 
after which a postcolumn split to divert roughly one-tenth of the sample to the mass 
spectrometer for molecular weight determination by electrospray ionization (ES11 mass 
spectrometry. The majority of the effluent is sent to a UV detector and ultimately collected as 
l-min fractions for biological testing. As a secondary confirmation of molecular weight, an 
aliquot of each fraction (< 5%) is taken for analysis by matrix-assisted laser desorption 
ionization (MALDI). The improved efficiency of this approach over more traditional schemes 
utilizing off-line fraction collection and conventional ionization methods can be explained by 
several factors. First, the superior sensitivity of ES1 and MALDI means that less material is 
required for successful analysis. Second, on-line LC/MS optimizes the efficiency of sample 
transfer and saves both time and labor. Furthermore, the concentration dependence of ES1 
allows a majority of the material injected for LC/MS to be recovered for biological testing 
without compromising the signal available for molecular weight determination. As a valida- 
tion of the above method, crude extracts containing two well-characterized 
antibiotics-teicoplanin and phenelfamycin-were examined. Results from these analyses 
are presented along with data from the analysis of a potent unknown antifungal sample. 
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T he need for new anti-infective agents is a well documented problem [l, 21. Because of the fre- quent and eventual tendency of pathogenic bac- 
teria to acquire resistance to current drugs, new antibi- 
otics are continually being sought. In recent years this 
problem has been exacerbated by several factors. For 
instance, it has been widely speculated that the overuse 
of antibiotics has accelerated the rate of mutation and 
ultimately resistance to current therapies [3]. Other 
contributing factors, such as the increased number of 
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immunocompromised patients due in part to the AIDS 
epidemic [4], have also contributed to a situation where 
novel antibiotic compounds are more in demand now 
than perhaps at any time in recent history. 
Although several strategies exist for the discovery 
of antibiotics [5-71, a majority of the work still consists 
of screening naturally occurring sources-most com- 
monly soil-in search of microorganisms that produce 
secondary metabolites inhibitory to target bacteria or 
fungi. Once such organisms are identified through 
microbiological screening [8, 91, they are subjected to 
large scale fermentation to obtain enough crude mate- 
rial for isolation and structural elucidation of the ac- 
tive substances. 
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Despite difficulties associated with structural eluci- 
dation of substances from fermentation broths, a far 
greater impediment to the discovery of new antibiotics 
is the fact that most isolated substances that show 
activity have previously been identified. Thus, a cru- 
cial step in the overall process is to establish whether 
or not a newly isolated substance indeed represents a 
new chemical entity. The process of establishing nov- 
elty is referred to as dereplicafion, as the aim is to avoid 
isolating and determining the structur6 of a substance 
that is not novel. 
At the beginning of the dereplication process a 
crude extract from a fermentation broth is fractionated 
by high-performance liquid chromatography (I-IPLC). 
A common practice is to perform photodiode array 
detection on-line during fractionation to establish the 
chromophor&) of the substances in the mixture [lo, 
111. The isolated fractions are then tested for biological 
activity, while mass spectrometric analysis is con- 
ducted in parallel to establish molecular weights for 
products residing in active fractions. If molecular 
weight determination is not successful, a further round 
of purification, biological testing, and mass spectrome- 
try must be conducted before a correlation of molecu- 
lar weight and activity can be obtained. 
Fortunately, it is possible to make an initial evalua- 
tion of novelty in the absence of complete structure 
elucidation. To aid in this determination, extensive 
data bases have been created that catalog bioactive 
molecules according to parameters such as the taxon- 
omy of the producer strain, the observed spectrum of 
activity, the method used for extraction/isolation, and 
physical data such as molecular weights and UV ab- 
sorption maxima [12, 131. Of the various types of 
information assembled, molecular weight is the most 
critical to an effective search since it affords a level of 
structural specificity not found with the other search 
parameters. Generally speaking, once molecular weight 
information is obtained it is possible to make an initial 
evaluation of novelty or to at least suggest further 
experiments needed to make a pivotal decision on 
whether or not to proceed with the time and labor 
intensive process of complete structural elucidation. 
Mass spectrometry has historically played an im- 
portant role in the structural characterization of antibi- 
otics [14, 151 and has been used in the process of 
novelty evaluation in our laboratory for a number of 
years. Typically, insertion probe techniques such as 
electron impact (EI), chemical ionization (CI), and fast 
atom bombardment (FAB) have been used. However, 
because of the limited scope and sensitivity of these 
methods, as well as the labor associated with process- 
ing and analyzing individual fractions, we sought to 
use liquid chromatography-mass spectrometry 
(LC/MS) for this purpose. 
A variety of LC/MS methods including direct liq- 
uid introduction 1161, thermospray [17], particle beam 
[181, and continuous flow FAB [19] have been applied 
to the analysis of antibiotics. However, none of these 
methods was considered reliable enough to be incor- 
porated into a high throughput scheme for antibiotics 
dereplication. With the availability of LC/MS inter- 
faces based on atmospheric pressure ionization (API) 
technology, this situation has changed dramatically. 
Although a number of reports have appeared in the 
literature that use either atmospheric pressure chemi- 
cal ionization (APCI) [20,21] or electrospray ionization 
(ESI) [22,23] for the analysis of antibiotics, surprisingly 
little attention has been given to the use of LC/MS for 
dereplication. 
Previously, we demonstrated the feasibility of liq- 
uid chromatography-electrospray ionization-mass 
spectrometry (LC-ESI/MS) for routine characterization 
of fermentation broth extracts [241. In this technique, 
crude extracts were fractionated by HPLC, and post- 
column effluent splitting was used to recover a major- 
ity of the sample for biological activity testing while 
ESI/MS supplied molecular weight information for 
components in the mixture. Since then, a similar strat- 
egy was adopted by Constant and Beecher [25] for 
dereplication of natural products derived from plant 
extracts. 
In this article, a detailed account is given on the 
procedure developed in our laboratory for the use of 
LC-ESI/MS for dereplication of antibiotic substances 
isolated from fermentation broths. At the core of the 
strategy presented is the use of on-line LC/MS to 
dramatically enhance the efficiency of the novelty de- 
termination process. The methodology described is il- 
lustrated in the analysis of fermentation broth extracts 
containing two well-characterized antibiotics as well as 
the analysis of an unknown antifungal sample. A 
unique feature of the strategy presented is use of 
matrix-assisted laser desorption ionization (MALDI) to 
serve as a secondary confirmation of the molecular 
weights determined by ESI. The results obtained per- 
mit discussion about the role and utility of both ioniza- 
tion techniques in the dereplication process. 
Experimental 
Materials 
All reagents used were of the highest quality available 
and were used without further purification. Acetoni- 
trile (CH,CN) was purchased from Burdick and Jack- 
son (Muskegon, MI). Water used for mobile phase 
preparation was purified by using a Millipore (Mil- 
ford, MA) Milli-Q water filtration system. Ammonium 
formate and ammonium bicarbonate were obtained 
from EM Science (Gibbstown, NJ). Formic acid (88%) 
was purchased from Fisher Scientific (Fair Lawn, NJ). 
a-Cyano+hydroxycinnamic acid was purchased from 
Aldrich Chemical Co. (Milwaukee, WI). 
Crude Antibiotics Preparation 
Crude teicoplanin complex was obtained by butanol 
extraction from the fermentation broth of Acfinoplunes 
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leichomyceticus ATCC 31121 as previously described 
1261. Crude phenelfamycin complex (GE21640 F VI 45) 
was obtained from the fermentation broth of Strepto- 
myces sp. GE21640. The filtered fermentation broth was 
extracted with ethyl acetate and the organic phase was 
concentrated under reduced pressure. The crude 
phenelfamycin complex precipitated upon addition of 
petroleum ether to yield an oily residue. Both strains 
belong to the Lepetit strain collection. The antifungal 
sample GE23845 EA II was also produced by microbial 
fermentation (full taxonomy not performed) and iso- 
lated by ethyl acetate extraction. To minimize antibi- 
otic degradation all procedures used in the isolation 
process were performed below 40 “C. Crude extracts 
were stored as solids in amber vials at -20 “C prior to 
analysis. 
Instrument Configuration for Liquid 
Chromatography-Mass Spectromet y 
Figure 1 shows a detailed representation of the instru- 
mental configuration used for LC/MS. The HPLC sys- 
tem consisted of a Waters 600MS pump and a Waters 
600E system controller (Waters Chromatography, Mil- 
ford, MA). Injections were made using a Rheodyne 
(Cotati, CA) 7725 injector equipped with a 20-PL exter- 
nal loop. Solutions for injection were prepared by 
dissolving a weighed amount of solid extract in mobile 
phase. Typically, 20-50 pg of crude fermentation broth 
extract was injected on-column and chromatographed 
by using gradient elution at a flow rate of 1 mL/min. 
The column used for all analyses was a 5-pm Nucle- 
osil Cl8 (4.6 mm X 25 cm) obtained from Phenomenex 
Figure 1. Diagram depicting the instnunental configuration used for mass spectrometry characteri- 
zation of crude fermentation extracts. The system consists of the following components: (1) HPLC, 
(2) loop injector, (3) guard column, (4) 5-pm Cl8 column (4.6 mm X 25 cm), (5) zero dead volume 
tee, (6) UV detector, (7) fraction collector, (8) triple quadrupole mass spectrometer equipped with 
ES1 interface, (9) ES1 power supply and gas manifold, and (10) syringe pump. Typically, 20-50 rg of 
a crude extract is injected and chromatographed by using an analytical bore HPLC column (4.~mm 
i.d.) at a flow rate of 1 ml/mm. A low dead volume tee located postcolumn is used to split about 
one-tenth of the effluent to a triple quadrupole mass spectrometer for ES1 analysis. The remainder of 
the effluent is sent to a UV detector and ultimately collected as fractions for biological activity 
assessment. An aliquot of each fraction (20-50 PL) is also taken for analysis by IvlALDI/MS serving 
as a second means for molecular weight determination. 
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(Torrance, CA) and protected by a Cl8 guard column. 
A Valco (Houston, TX) zero dead volume tee was used 
postcolumn to effect a 1:lO effluent split diverting a 
majority of the sample to a Waters 486 tunable ab- 
sorbance detector by using O.OlO-in. i.d. poly- 
etheretherketone (PEEK) tubing. The remainder of the 
flow (- 0.1 mL/min) was delivered to the ES1 inter- 
face of a Finnigan MAT (San Jose, CA) TSQ 700 triple 
quadrupole mass spectrometer through 0.005-m i.d. 
PEEK tubing. Prior to fraction collection the UV ab- 
sorbance was monitored on-line. A wavelength of 254 
nm was used for the analysis of teicoplanin, while 230 
run was used for both the analysis of phenelfamycin 
and GE23845 EA II. The effluent exiting the UV detec- 
tor was collected as l-min fractions into polypropylene 
microcentrifuge tubes. A 20-50-FL aliquot of each 
fraction was removed for subsequent analysis by 
MALDI, while the remainder was concentrated to dry- 
ness using a Speed Vat Concentrator (Savant Instru- 
ments, Farmingdale, NY) and submitted for microbio- 
logical testing. 
High-Performance Liquid Chromatography 
Gradient Formation 
All chromatography was performed by using varia- 
tions of a binary solvent system composed of CH,CN 
and an ammonium formate buffer. For the analysis of 
teicoplanin complex a 2-g/L ammonium formate buffer 
was prepared in water and adjusted to pH 4 by using 
formic acid. For all other analyses, ammonium formate 
was prepared in water (1 g/L) and used without pH 
adjustment. For teicoplanin, mobile phase A was pre- 
pared as (5/95) CH,CN/buffer (v/v>, while mobile 
phase B was composed as (70/30) CH,CN/buffer 
(v/v). A linear gradient from 10 to 40% B was per- 
formed over 40 min. 
Chromatographic separation of phenelfamycin com- 
plex and the antifungal sample GE23845 EA lI were 
each accomplished by using the following mobile phase 
combination. Mobile phase A was (5/95) CH,CN/ 
buffer (v/v) and mobile phase B consisted of (80/ 20) 
CH,CN/ buffer (v/v). For the phenelfamycin analysis, 
a linear gradient from 50 to 90% B over 20 min was 
employed. For the antifungal sample, a linear gradient 
from 30 to 70% B was performed over 40 min followed 
by a ramp to 100% B by 45 min. 
Electrospruy lonization Mass Spectromet y 
The ES1 interface used was provided by Finnigan MAT 
and used without modification. The liquid chromatog- 
raphy (LC) effluent (- 0.1 mL/rnin) was introduced 
through the sample inlet port in the center of the ES1 
probe and exited through the stainless steel ES1 needle 
(26 gauge) held at a potential of 5.5 kV. The ES1 needle 
was located roughly 2 cm from the heated stainless 
steel capillary orifice (0.5~mm i.d.) that separated the 
ES1 spray at atmosphere from the high vacuum condi- 
tion of the.mass spectrometer. The capillary was heated 
to 200 “C for all analyses. To further assist desolvation, 
a nitrogen sheath gas (60 lb/in21 was introduced 
through the ES1 probe coaxially around the ES1 needle. 
In the case of phenelfamycin a liquid sheath, sand- 
wiched between the sample and gas flows, was intro- 
duced through the ES1 probe. To promote cationiza- 
tion, a potassium bicarbonate solution prepared by 
using tap water (1 mg/mL) was introduced at a rate of 
10 pL/min by using a Harvard syringe pump. All 
mass spectra were acquired by using Q3 as the scan- 
ning quadrupole. A mass range of m/z 250-2000 was 
covered with a scan time of 3 s. All data were collected 
in the positive ion mode by using an electron multi- 
plier voltage of 1200 V and a conversion dynode po- 
tential of -15 kV. 
Matrix-Assisted Laser Desorption 
Ionization-Time-of-Flight Mass Spectromet y 
MALDI analysis was performed by using a Fisons 
TofSpec (Manchester, UK) linear time-of-flight (TOF) 
instrument equipped with a nitrogen laser (337 run, 
4-ns pulse) and a 0.7-m flight tube. An accelera- 
tion potential of 20 kV was used for all experi- 
ments. Aliquots removed from I-IPLC fractions were 
mixed 1:3 (v/v) with a-cyano+hydroxycinnamic acid 
(CHCA) prepared as a lo-mg/mL solution in 60/40 
CH,CN/O.l% trifluoroacetic acid (TEA) in water (v/v>. 
One microliter of an aqueous solution of KC1 (- 30 
nmol) was then added to this mixture. After mixing, 2 
PL of this combined solution was transferred to the 
stainless steel MALDI target and allowed to air dry 
prior to analysis. For the phenelfamycin experiment, 
renin substrate tetradecapeptide (porcine sequence) 
was added to each sample as an internal mass refer- 
ence standard (monoisotopic mol. wt. 1758.9) to achieve 
a level of 5 pm01 on target. 
Microbiological Testing 
Teicoplanin was tested against Staphylococcus aureus 
(Isosensitest agar medium containing an inoculum of 
lo6 cells/ml). Phenelfamycin complex GE21640 F VI 
45 was tested against Moraxella caviae (Todd-Hewitt 
agar medium, lo6 cells/ml). The antifungal sample 
GE23845 II EA was tested against Candidn albicans 
(Sabouraud agar medium, lo6 cells/ml). To facilitate 
microbiological testing, each I-IPLC fraction was recon- 
stituted in the appropriate buffer. In each case, a lo-PL 
aliquot of each fraction was deposited onto the agar 
surface containing the target organism and incubated 
for 24 h at 37 “C. Biological activity was expressed as 
the diameter of the observed zone of inhibition in 
millimeters. 
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Results 
Teicoplanin 
The first sample analyzed was a crude extract obtained 
from a production scale fermentation of the known 
anti Gram positive antibiotic teicoplanin. The structure 
shown in Figure 2 indicates teicoplanin to be a gly- 
copeptide whose peptide backbone is fused among an 
extensive network of ring structures forming the pla- 
nar core of the molecule. As many as three sugar 
residues may be attached to the core structure. Func- 
tionally, the most important sugar is the N-acyl glu- 
cosamine which, as indicated in Figure 2, may be 
substituted with a number of fatty acids. Variation in 
the associated acyl chain (R) accounts for the primary 
source of heterogeneity in teicoplanin-related struc- 
tures. 
Data obtained from the analysis of 40 pg of a crude 
teicoplanin extract are shown in Figure 3. The upper 
two panels display the UV absorbance at 254 run and 
the ES1 total ion current (TIC) from LC/MS analysis. 
The lower panel is a histogram expressing the biologi- 
cal activity present in each I-IPLC fraction against the 
bacterium Staphylococcus aureus. In this example, ex- 
tremely close agreement was observed between all 
three sets of data, making it possible to correlate ob- 
served biological activity with specific components in 
the teicoplanin mixture. 
The peak assignments appearing on the UV trace in 
Figure 3 indicate that the major species present in the 
mixture belong to the A2 structural family of te- 
icoplanin. To a first approximation, retention of te- 
icoplanin-related structures under reverse phase Cl8 
conditions is determined by the nature of the fatty acid 
side chain (R). For example, the isomeric species A2-4 
and A2-5 are more highly retained than the corre- 
sponding pair of isomers A2-2 and A2-3, which contain 
one less methylene unit. This effect also explains the 
early elution of the A3-1 species, which lacks the 
Wacyl fatty acid-containing sugar. 
A summary of the mass spectrometric data for te- 
icoplanin appears in Table 1. In this table, assignments 
R 
Figure 2. Structures for the major components of teicoplanin. 
Structural heterogeneity occurs primarily from variation in the 
fatty acid side chain associated with the N-acyl group (desig- 
nated by the letter RX 
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Figure 3. Chromatographic and biological activity profiles re- 
sulting from the analysis of 40 pg of a crude fermentation extract 
containing the Gram positive antibiotic teicoplanin. The upper 
and middle panels display the UV absorbance (2% run) and ES1 
total ion current U’ICl, respectively, from on-line LC-UV-ESI/ MS 
analysis. The histogram in the bottom panel expresses the micro- 
biological activity for each fraction collected from HPLC against 
Staphylococcus aureus. Activity is expressed as the inhibition zone 
(millimeters), which refers to the diameter of a circular area on 
an agar plate inoculated with a test microorganism where growth 
has been inhibited by the presence of an antibiotic substance. 
are given for the major component present in each 
active fraction along with the proposed difference in 
elemental formula relative to A2-2, the most abundant 
form of teicoplanin. The assignments were based on 
molecular weights determined by ES1 and MALDI 
along with the extensive knowledge available for this 
mixture 127. 281. 
The ES1 data in Table 1 are listed in terms of 
monoisotopic mass. The ES1 data are represented in this 
fashion because the quadrupole mass analyzer used 
permitted resolution of the individual isotopes in the 
molecular ion clusters. In contrast, the comparatively 
limited mass resolution of time-of-flight (TOF) did not 
allow individual isotopes to be distinguished by 
MALDI. Consequently, these data appear as average 
mass. Another difference is that the MALDI molecular 
ions are listed as [M + K]+, instead of [M + HI+, 
reflecting the addition of KC1 during MALDI sample 
preparation. 
A representative example of the mass spectral data 
obtained by the two ionization methods appears in 
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Table 1. Mass spectrometric data summary for teicoplanin’ 
Active Formula [M + HI+ talc. [M + HI’ [M + Kl+ talc. [M + KI+ 
fractionb ldentityC relative to AZ-2 monoisotopic ESI average MALDI 
19 
22 
31 
33 
34 
34 
35 
36 
37 
37 
38 
38 
39 
42 
43 
44 
A3-1 
(A3-1) - HexNAc 
A2-1 
(A2-2) + Hex 
A2-1 
A2-2 
A2-3 
(A2-2) - Hex 
(A2-4) + Hex 
A2-4 
A2-5 
W-1 
RS-2 
-~6’-bsNO5 
-G,HaN201o 
-W 
-Y 
C6w%, 
-“2 
- 
Isomer 
Isomer 
-‘%05’%0 
+C705H,2 
+CH, 
+CH 2 
-H2 
1563.4 1563.3 1603.4 1601 
1360.3 1360.1 1400.2 n.d. 
1864.5 1864.9 1904.8 1906 
1876.5 1876.4 1916.8 1916 
2040.6 2041.2 2080.9 2083 
1876.5 1876.6 1916.8 1918 
1878.6 1878.9 1918.8 1915 
1878.6 1878.8 1918.8 1918 
1878.6 1878.5 1918.8 1918 
1716.5 1716.3 1756.7 n.d. 
2054.6 2055.6 2095.0 n.d. 
1892.6 1892.7 1932.8 nd. 
1892.6 1892.5 1932.8 1929 
1876.5 1876.8 1916.8 nd. 
1906.6 1906.3 1946.9 1947 
1906.6 1906.2 1946.9 1945 
’ Hex = hexose; HexNAc = N-acetylglucosamine; n.d.= not detected. 
b See histogram in Figure 3. 
‘For structural assignments refer to Figure 2. 
Figure 4. In this figure, the ES1 mass spectrum for 
teicoplanin component A2-5 is displayed. The inset 
appearing on this spectrum shows the corresponding 
MALDI data for A2-5 which eluted in fraction 39. Two 
molecular ion types were observed by ESI: the proto 
nated molecule as well as an ammonium adduct. The 
protonated molecule was expected as the molecule 
contains a basic site located at the N-terminus. The 
ammonium adduct, on the other hand, can be ex- 
plained by the presence of ammonium formate in the 
mobile phase used. Characteristic of ESI, multiple pro 
tonation of the molecule resulted in a doubly charged 
ion at m/z 947.5. In contrast, the MALDI data in 
Figure 4 indicate a series of cationized adducts pro- 
duced by sodium and/or potassium. The peaks indi- 
cated were the only analyte-related ions in the mass 
d+NW 
Figure 4. Mass spectral data for teicoplanin component AZ-5. 
The FSI mass spectrum was acquired on-line by LC/MS. The 
MALDI data (inset) were obtained from fraction 39 (Figure 3). 
spectrum as no fragment ions were observed. The 
nature of these adducts reflects a relatively high level 
of salt in the sample due in part to the addition of KC1 
during MALDI sample preparation. 
The biggest difference observed between the two 
ionization methods was in the extent of fragmentation 
observed. Strictly speaking, both ES1 and MALDI are 
extremely soft ionization methods that do not produce 
fragment ions. It is apparent from the mass spectrum 
of the A2-5 component in Figure 4 that this was not the 
case for ESI. This phenomenon has been traced to the 
heated capillary orifice of the ES1 interface, which was 
held at a temperature of 200 “C. In the present exam- 
ple, two fragment ions were observed: the loss of a 
hexose moiety (m/z 1730) and the removal of the 
N-acyl fatty acid sugar (m/z 1563). Although these 
ions are structurally informative, the structural assign- 
ments given in Table 1 were based on existing struc- 
tural information available for this mixture obtained 
by a number of methods including NMR [27, 281. 
Hence, it is important to clarify that it would not be 
possible to make detailed structural assignments, such 
as the differentiation of isomers, from ES1 alone. 
Phenelfamyciris 
The second class of molecules investigated was the 
phenelfamycins [29], which are part of a broader fam- 
ily of antibiotic molecules known as elfamycins. The 
name elfamycin is derived from the mode of action of 
these molecules, which is to inhibit the elongation 
factor Tu involved in bacterial protein synthesis [30, 
311. The structure and nomenclature for the phenelfa- 
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Figure 5. Structures for the phenelfamycin class of antibiotics. 
As indicated by the inset on the figure, phenelfamycins have 
been assigned letter designations according to their substitution 
at positions Rl, R2, and R3. 
mycin-related molecules identified in this study ap- 
pear in Figure 5. 
The sample analyzed, GE21640 F VI 45, was isolated 
from a 4-L fermentation of the Streptomyces sp. GE21640 
known to produce phenelfamycin-related antibiotics. 
As was the case for teicoplanin, extracts from previous 
fermentation of this strain had been extensively char- 
acterized prior to this study. The data obtained from 
the analysis of 50 pg of this sample are reported in 
Figure 6. The upper two panels in this figure represent 
UV (230 nm) and ES1 total ion current (TIC) from the 
LC/MS analysis, while the lower panel displays in 
histogram form the biological activity against Moraxeh 
cuviae for each fraction isolated. Again, a clear align- 
ment was evident among all three sets of data. 
The mass spectrometry data corresponding to the 
material in fraction 16, identified as phenelfamycin E, 
are shown in Figure 7. This figure displays the ES1 
mass spectrum for this product along with the molecu- 
lar ion region observed by MALDI (inset). In contrast 
to teicoplanin, [M + Na]+ was the dominant ion ob- 
served by both ionization methods. A potassium 
adduct was also present in each spectrum owing to the 
conditions used for analysis. 
The failure to observe [M + HI+ is attributed in 
part to the phenelfamycin structure which lacks a basic 
site. Another explanation is that [M + H]+ is unstable, 
thus accounting for the extensive fragmentation ob- 
served in Figure 7. The ion at m/z 744 is explained by 
successive losses of methanol and S3-OH from the 
protonated molecule, where S3 stands for the trisac- 
charide substituent at position R3 (Figure 5). The fur- 
ther loss of benzoic acid from the terminus of the 
molecule accounts for the base peak at m/z 622. This 
latter fragmentation was not observed for the corre- 
sponding isomer phenelfamycin F, which instead un- 
dergoes a favorable 1,4-elimination of phenyl acetic 
acid B-OH to yield an ion of m/z 608 (data not 
shown). A similar pattern of fragmentation permitted 
differentiation of the other isomeric pairs in the mix- 
AC 
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Figure 6. Chromatographic and biological activity profiles re- 
sulting from the analysis of 40 pg of a crude extract obtained 
from fermentation of the bacterial strain GE21640 F VI 45, known 
to produce phenelfamycin antibiotics. The upper and middle 
panels display the UV absorbance (230 run) and ES1 total ion 
current (TIC), respectively, from on-line LC-UV-ESI/MS analysis. 
The histogram in the bottom panel expresses the microbiological 
activity for each fraction collected from HPLC against Moraxella 
caviue. Activity is expressed as the inhibition zone (millimeters), 
which refers to the diameter of a circular area on an agar plate 
inoculated with a test microorganism where growth has been 
inhibited by the presence of an antibiotic substance. 
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Figure 7. Mass spectral data corresponding to phenelfamycin E. 
The ES1 mass spectrum was acquired on-line by LC/MS, while 
the MALDI data (inset) were obtained from fraction 16 (Figure 
6). 
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Table 2. Mass spectromehic data summary for phenelfamycin sample GE21640 F VI 45a 
Active Ret. time Mol. wt. [M + KI+ [M + KI+ Key fragment 
fractionb (min) monoisotopic ESI MALDI Identity’ ions (m/z) 
8 8:40 819.4 858.2 n.d. UN-l 626,504 
9 9:15 963.5 1002.4 n.d. UN-2 626,504 
12 n.a n.a. n.d. n.d. unk n.a. 
13 13145 829 868.2 n.d. unk n.a. 
14 14:30 973 1002.4 n.d. unk n.a. 
14 14:40 937.5 976.2 976 A 744.622 
15 15:30 1081.6 1120.3 1121 C T  744.622 
16 16:25 1225.6 1264.3 1263 E 744,622 
17 17:35 937.5 976.4 976 B 744,608 
18 18:20 1081.6 1120.2 1121 D 744,608 
19 19:15 1225.6 1264.4 1263 F 744,608 
19 19:40 927 966.3 n.d. unk n.a. 
a “.a.= not applicable; n.d.= not detected; unk = unknown 
bSee histogram in Figure 6. 
‘For structural assignments refer to Figure 5. 
ture. The specific ions used to make these assignments 
are included in the mass spectrometry data summary 
for phenelfamycin sample GE21640F VI 45 (Table 2). 
Verrucarins 
The methodology described above for teicoplanin and 
the phenelfamycins was applied to the analysis of an 
unknown fermentation extract exhibiting potent anti- 
fungal activity. An injection of 40 p*g of a crude extract 
(sample GE23845 EA II) produced the data in Figure 8. 
This experiment was significant to the dereplication 
process because the molecular weights identified (Ta- 
ble 3) permitted a successful search of a data base 
constructed in-house for novelty assessment. These 
data when combined with other information including 
knowledge about the producer strain, spectrum of 
activity, and UV absorbance (A,,, = 260 nm) sug- 
gested that the material isolated belonged to the known 
verrucarin family of toxic antifungal agents [32]. The 
structure for verrucarin A, one of the predominant 
members of this family, appears in Figure 9. This 
suspicion was corroborated by further study including 
a toxicological profile (unpublished results). Due to the 
toxicity of this substance, along with the various evi- 
dence suggesting the verrucarin family, further work 
toward isolation and detailed structural elucidation 
was not warranted. 
The molecular weight of each component in the 
verrucarin crude was readily derived from a character- 
istic grouping of molecular ions, the most intense of 
which was the ammonium adduct. This pattern is 
illustrated in Figure 10 (upper panel) which displays 
the molecular ion region in the ES1 mass spectrum 
corresponding to the component eluting in I-IPLC frac- 
tion 25. The ammonium adduct at m/z 550 is flanked 
by the protonated molecule at m/z 533 and the sodium 
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Figure 8. Chromatographic and biological activity profiles re- 
sulting from the analysis of 40 pg of a crude extract obtained 
from fermentation of the bacterial strain GE23845 EA II. Un- 
known components in this crude had previously demonstrated 
potent antifungal activity. The upper and middle panels display 
the UV absorbance (230 m-n) and ES1 total ion current (TIC), 
respectively, from on-line LC-UV-ESI/MS analysis. The his- 
togram in the bottom panel expresses the antifungal activity for 
each fraction collected from HPLC against Cundida albicans. Ac- 
tivity is expressed as the inhibition zone (millimeters), which 
refers to the diameter of a circular area on an agar plate inocu- 
lated with a test microorganism where growth has been inhibited 
by the presence of an antibiotic substance. 
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Table 3. Mass spectrometric data summary for antifungal 
sample GE23845 EA II” 
Active [M + NH,]+ tM + NH,]+ Molecular 
fractionb ESI MALDI weight 
25 550.2 551 532 
26 550.2 549 532 
26 624.3 624 606 
27 520.2 520 502 
28 592.2 n.d. 574 
29 n.d. n.d. 
32 548.2 n.d. 530 
33 546.2 544 528 
33 590.2 n.d. 572 
34 518.2 516 500 
35 532.2 531 514 
38 530.2 n.d. 512 
39 532.2 n.d. 514 
a n.d.= not detected. 
bSee histogram in Figure 8. 
Verrucarin A 
Figure 9. Structure of verrucarin A, one of the main members of 
the verrucarin family of toxic antifungal agents. 
and potassium adducts at m/z 555 and 571, respec- 
tively. In contrast, only the ammonium adduct was 
observed by MALDI (Figure 10, lower panel). To- 
gether, these data unambiguously confirm the molecu- 
lar weight assignment for the active substance in frac- 
tion 25 as 532 u. 
Discussion 
Mass spectrometry has long played a significant role in 
the dereplication of natural products isolated from 
fermentation broths. Typically, mass spectrometry is 
incorporated as part of an iterative cycle involving 
purification, biological activity, and molecular weight 
determination. This traditional approach to novelty 
evaluation often becomes a bottleneck step in the dis- 
covery process. Since each round of analysis involves 
fraction collection, sample processing, and analysis 
(biological and spectroscopic), the overall procedure is 
-.- 
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Figure 10. Comparison of ES1 (top spectrum) and MALDI (lower 
spectrum) data for an unknown antifungal agent eluting in 
fraction 25 (Figure 8). The large ammonium adduct in each 
spectrum is attributed to the mobile phase used. Several addi- 
tional molecular adducts observed in the ES1 spectrum enabled 
the molecular weight to be unambiguously assigned as 532 u. 
very time and labor intensive. The common use of 
insertion probe mass spectrometry methods is another 
source of inefficiency. One problem stems from incom- 
plete recovery as individual fractions are concentrated 
and transferred to the mass spectrometer for analysis. 
This factor, coupled with the limited sensitivity of 
older ionization methods (EI, CI, or FAB), increases the 
total sample needed for molecular weight determina- 
tion. Unfortunately, when molecular weight data are 
not obtained, a further iteration of the purification/ 
analysis cycle must occur and the time taken for nov- 
elty assessment is increased accordingly. 
The methodology for mass spectrometry utilization 
described in this paper imparts several advantages to 
the dereplication process. First, due to the sensitivity 
of ES1 and MALDI, less material must be isolated for 
analysis. Second, the on-line nature of LC/MS reduces 
the labor associated with fraction collection and sam- 
ple processing. LC/MS also optimizes sample transfer 
to the mass spectrometer and retains the chromato- 
graphic resolution lost in the process of fraction collec- 
tion. A further consideration in the experimental de- 
sign was the concentration dependence of ES1 [33]. 
Because ESI/MS acts as a concentration-sensitive de- 
tector, it was possible to split the effluent postcolumn 
for fraction collection without unduly compromising 
molecular weight determination. In the present strat- 
egy, roughly 90% of the injected crude was recovered 
for microbiological testing. 
Valid molecular weight determination is essential to 
a dependable dereplication strategy, as it is often the 
only structural information available for novelty evalu- 
ation. More sophisticated techniques are typically lim- 
ited by the amount of sample available and its purity. 
It was for this reason that the methodology presented 
allows for two separate determinations of molecular 
weight. This feature can be extremely useful when 
analyzing unknown samples as it is difficult to know a 
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priori which type of molecular adduct ion will pre- 
dominate. The intentional introduction of specific salts 
(e.g., KCl) was another method used in this study to 
ensure valid molecular weight determination. 
A separate but related issue involves the reliability 
of molecular weight-based searches for natural prod- 
ucts dereplication. This concern was recently ad- 
dressed by Constant and Beecher [25], who demon- 
strated that searches of the NAPRALERT data base 
(over 80,000 known compounds) by using only chemo- 
taxonomy, pharmacology, UV-visible spectroscopy, 
and molecular weight permitted successful dereplica- 
tion of several natural product extracts. 
To our knowledge, this work represents the first 
reported use of MALDI specifically for antibiotics 
dereplication. The main advantage of MALDI is that it 
is a rapid technique that can be used to survey indi- 
vidual fractions submitted for biological testing. Fur- 
thermore, because fractions may be sampled without 
preconcentration, a majority of the material is available 
for biological testing. In spite of these advantages, it is 
our initial assessment that MALDI should not be used 
as a stand alone method for characterization of crude 
antibiotic mixtures. The data acquired in this study 
(Tables l-3) indicate a number of instances where a 
molecular weight was identified by ESI, but not by 
MALDI. One explanation for this result is inadequate 
sample preparation, a subject which needs to be more 
thoroughly investigated. However, even when ade- 
quate signal was obtained, the poor mass resolution of 
linear TOF frequently resulted in compromised mass 
accuracy. The role of MALDI is therefore probably best 
viewed as an adjunct to LC-ESI/MS used on an as- 
needed basis to corroborate assignments made by ESI. 
Improvements in TOF, such as delayed extraction and 
reflectron mass analysis [341, may overcome some lim- 
itations experienced in this study. 
A topic not considered in the present experimental 
design was the acquisition of tandem mass spectrome- 
try (MS/MS) data. The usefulness of this approach 
was recently demonstrated by Julian [35], who used 
ESI/MS/MS with ion trap detection for antibiotics 
dereplication. MS/MS is a logical extension to the 
work presented here as it offers a facile means to 
increase the certainty of novelty evaluation. In addi- 
tion, it could be used with either ionization technique. 
Two fundamental limitations to MS/MS, however, are 
the lack of available reference standards and difficulty 
in interpreting spectra for unknown structures. For 
these reasons, the most appropriate use of MS/MS 
would be to reject or confirm structural assignments 
proposed from data base searches conducted using 
molecular weight data acquired by LC/MS. 
The methodology outlined in this paper has been 
implemented in our laboratory for over two years. 
Although it is difficult to estimate, the time required to 
arrive at an initial determination of novelty is typically 
on the order of one week. By comparison, under the 
traditional approach involving fraction collection and 
classical ionization techniques, this same process could 
take several weeks and in some instances months. In 
all cases, a key objective is always to minimize the 
number of iterative purification/analysis steps re- 
quired for novelty evaluation. The on-line efficiency of 
LC/MS along with the superior sensitivity of ES1 and 
MALDI enables a situation where novelty determina- 
tion can proceed with less labor and greater clarity. 
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